Completed PHASE1 INTERVENTIONAL 2-arm NCT01054937

Single Dose Study With 4SC-203 in Healthy Volunteers

First-in-Man, Randomised, Double-Blind, Placebo-Controlled, Single Dose Escalation Study of the Novel Compound 4SC-203 in Young Healthy Volunteers

Sponsor: 4SC AG

Conditions Acute Myeloid Leukemia

Interventions 4SC-203 Placebo

Updated 5 times since 2017 Last updated: Jan 12, 2011 Started: Jan 31, 2010 Primary completion: Nov 30, 2010 Completion: Nov 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01054937, this PHASE1 trial focuses on Acute Myeloid Leukemia and remains completed. Sponsored by 4SC AG, it has been updated 5 times since 2010, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jan 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

4SC AG

Data source: 4SC AG

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Berlin, Germany